Latest Physician Fee Schedule Proposal Could Impact Companies’ Bottom Line
Executive Summary
The US Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes new reimbursement levels for multiple medical devices, including the Glaukos iStent.
You may also be interested in...
Glaukos Takes Another Hit From CMS; Investors Respond Negatively As Stock Falls
The US Medicare agency's new rule for facility fees brings more bad news for Glaukos; Wells Fargo downgrades company’s stock in response.
Proposed Medicare Code Change Could Affect Reimbursements On Glaucoma Devices
A proposed change to US Medicare billing that would go into effect 1 January might give one manufacturer an edge over its competitor.
iRhythm Is ‘Encouraged’ By Recent Reimbursement Discussions With Novitas
The company provided another update on its ongoing efforts to secure adequate Medicare reimbursement for long-term continuous cardiac monitoring.